Scott Requadt

Scott Requadt is currently President, Chief Executive Officer & Director at Prolium Bioscience, Inc., Director at Variation Biotechnologies (US), Inc., and Legal Advisor at Phoenix Strategy Investments LLC.
Formerly, Mr. Requadt was President, Chief Executive Officer & Director at Talaris Therapeutics, Inc. from 2018 to 2023.
Other former roles include Director positions at Biolex Therapeutics, Inc., TYRX, Inc., Link Medicine Corp., Astria Therapeutics, Inc., Oxford Immunotec Global Ltd., Quest Diagnostics TB LLC, eDev SARL, Verband Beratender Ingenieure VBI, and VBI Vaccines, Inc. Independent Director at VBI Vaccines, Inc. from 2016 to 2019, Independent Director at AVROBIO, Inc. from 2016 to 2018, Independent Director at ESSA Pharma, Inc. from 2016 to 2025, Venture Partner at Clarus Lifesciences III LP from 2018 to 2020, Attorney at Davis Polk & Wardwell LLP from 1995 to 1999, Director-Business Development at TransForm Pharmaceuticals, Inc. from 2001 to 2004, Transactional Partner at Clarus Ventures LLC from 2010 to 2012, and Partner at Blackstone, Inc. from 2018 to 2022.
Education includes undergraduate studies at McGill University, graduate studies at the University of Toronto, and an MBA from Harvard Business School.